Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Launched by UNIVERSITY OF BERN · Aug 18, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) is a study that aims to gather important information about various inflammatory brain diseases affecting children in Switzerland. This registry collects details on the diagnosis, symptoms, treatments, and follow-up care for children under 18 who have specific conditions, such as optic neuritis, multiple sclerosis, or autoimmune encephalitis. By participating, children and their families can help researchers and doctors better understand these diseases, leading to improved treatments and better quality of life for young patients.
To join the study, participants must be under 18 years old and living in Switzerland with one of the listed conditions. They will need to provide written consent, either themselves or through a legal representative. The registry is currently recruiting participants, and the process involves sharing health information that will be used for research and to enhance healthcare for children with these serious conditions. Overall, this initiative is designed to support research and foster collaboration among healthcare professionals to improve outcomes for young patients dealing with inflammatory brain diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.
- • Written informed consent by patients (and/or legal representative(s), if applicable)
- • Optic Neuritis
- • Transverse Myelitis
- • Acute disseminated encephalomyelitis
- • Multiple Sclerosis
- • Neuromyelitis Optica Spectrum Disorders
- • Myelin oligodendrocyte glycoprotein antibody-associated disease
- • Anti-NMDA-R Encephalitis
- • Anti-GAD65 Associated Autoimmune Encephalitis
- • Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
- • Anti-Lgi-1 Associated Autoimmune Encephalitis
- • Anti-CASPR-2 Associated Autoimmune Encephalitis
- • Anti-GABAR-1/2 Associated Autoimmune Encephalitis
- • Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
- • Hashimoto Encephalopathy
- • CNS Vasculitis
- • CNS Sarcoidosis
- • CNS Lupus
- • Rasmussen Encephalitis
- Exclusion Criteria:
- • Neurological symptoms due to infectious diseases of the CNS
- • Genetic/metabolic causes of central demyelinating diseases
- • Neurological symptoms due to Guillain-Barré-Syndrome
About University Of Bern
The University of Bern, a leading research institution in Switzerland, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment where scientific inquiry and clinical application intersect. Its commitment to ethical standards and patient safety ensures that all trials are conducted with the highest integrity, striving to contribute valuable insights to the global medical community. The University of Bern actively engages in diverse therapeutic areas, aiming to translate research findings into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chur, , Switzerland
Luzern, , Switzerland
Aarau, Aargau, Switzerland
Chur, Graubünden, Switzerland
Zurich, , Switzerland
Geneva, , Switzerland
Winterthur, Zurich, Switzerland
St.Gallen, Saint Gallen, Switzerland
Bellinzona, Ticino, Switzerland
Lausanne, Vaud, Switzerland
Winterthur, Zurich, Switzerland
Basel, , Switzerland
Bern, , Switzerland
Bern, , Switzerland
Fribourg, , Switzerland
Luzern, , Switzerland
Patients applied
Trial Officials
Sandra Bigi, PD MD
Principal Investigator
ISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern
Sandra Bigi, PD MD
Study Director
ISPM, University of Bern, Bern Kinderspital Zentralschweiz, Luzern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials